Clinical Trials for Cancer Treatment

Study Title:

AFT-65: ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in patients with high-risk early triple-negative breast cancer when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.

Upstate Institutional Review Board (IRB) Number:

2091588

Study/Protocol ID:

AFT-65, ASCENT-05, OptimICE-RD, GS-US-59

Study Phase:

Phase 3

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

What is involved if I participate?

How long is the study?
Your total time in the study will vary depending on how you respond to study treatment. Taking part in this study may last from 1 day up to 10 years or longer, if you agree to remain in the study, your cancer has not returned, or the study is not stopped.
Is transportation provided or reimbursed?
Yes
Is parking provided or reimbursed?
No
What tests and procedures are involved?
If you join the study, you will have more exams, tests, and procedures to closely monitor your safety and health.